As a new type of foreign trade service provider driven by dual engines of technology commercialization and foreign trade services, HiSiaddi has built a "1+2+3+4=1" service system and can supply original factory materials of multiple well-known brands for Bile Acid.
As an R&D-focused foreign trade service provider, unlike single-brand factories that only promote their own products, we objectively analyze multiple high-market-share leading brands in China and worldwide, and share their major technological process advancements and breakthroughs to provide buyers with authentic, up-to-date market insights.
If you require more comprehensive and valuable Bile Acid market intelligence, please contact HiSiaddi customer service.
1.
Breakthrough Details Chuan Ning Biotech launched self-developed one-step dual-enzyme coupling mass production technology, boosting the directional conversion rate of hyodeoxycholic acid to Ursodeoxycholic Acid (UDCA) from 67% via traditional chemical synthesis to 90.2%. The process eliminates 3 high-temperature acid-base reaction steps, cutting chemical auxiliary consumption per ton of product by 62% and by-product generation by 43%, with full mass production of 120 tons/year pharmaceutical-grade UDCA API launched in 2025. Shengda Bio completed pilot testing of CDCA chenodeoxycholic acid enzymatic conversion, lifting conversion yield from 69% to 89.1% and eliminating reliance on scarce goose gallbladder raw materials; mass production using low-cost pig and duck bile is now feasible.
2.
3.
Downstream Benefits ① Overseas pharmaceutical buyers see a 14%–18% year-on-year drop in UDCA raw material purchasing unit prices, eliminating secondary intermediate purification steps and reducing pharmaceutical formulation processing costs by 9%. ② Supply stability improves year-round without price volatility from global specialty gallbladder raw material shortages, cutting inventory stockpiling requirements by 25%.
4.
1.
Breakthrough Details Longchang Animal Protection and Yungang Bio deployed batch nanofiltration + Simulated Moving Bed (SMB) coupled purification systems to replace traditional intermittent column chromatography. Total feed-grade bile acid purity rose from 88% to ≥95%, while pharmaceutical-grade UDCA monomer purity reaches ≥99.5%, with single unknown impurities ≤0.08% and heavy metals As/Pb <0.5ppm. SMB technology raises organic solvent recovery from 52% to 86%, slashing solvent consumption per ton of product by 61%. Hepalink’s injectable-grade bile acid passed full FDA impurity review, with all 15 related substances meeting the latest USP pharmacopoeia limit standards.
2.
3.
Downstream Benefits ① Raw materials from manufacturers of European and American health supplements and pharmaceuticals can be directly used for DMF filings and formulation applications, eliminating incoming re-purification and shortening new product launch cycles by 22%. ② Aquatic and livestock feed manufacturers reduce addition rates by 12% while maintaining equivalent liver protection and absorption promotion effects, lowering formula soybean meal ratios and cutting terminal aquaculture feed costs by 7%–9%.
4.
1.
Breakthrough Details Yungang Bio realized mass production of full-component separation technology for mixed waste livestock bile, enabling simultaneous extraction of CA, CDCA, and DCA monomers from discarded mixed pig, chicken, and duck gall cream. Comprehensive raw material utilization rose from 59% to 87%, fully utilizing slaughter waste by-products. All leading production lines completed closed-loop wastewater recycling renovations, cutting wastewater discharge per ton of product by 38% and capping COD emissions below 60mg/L to meet EU REACH carbon verification requirements.
2.
3.
Downstream Benefits ① Buyers can purchase mixed monomer raw materials for on-demand formulation blending, reducing logistics costs from separate procurement of multiple material categories. ② Products pass customs without additional EU carbon tariff surcharges, avoiding import cargo detention risks stemming from environmental compliance issues.
4.
1.
Breakthrough Details Longchang Animal Protection launched mass production of microcapsule coated bile acid, boosting gastric acid resistance and animal intestinal bioavailability by 23%. Active ingredient loss during 24-month ambient storage dropped from 11% to 2.8%, resolving deterioration issues during high-temperature ocean shipping and suiting tropical and Southeast Asian long-distance transport.
2.
3.
Downstream Benefits Southeast Asian and South American aquatic feed buyers eliminate cold-chain storage requirements, drastically cutting warehouse loss rates and reducing aquatic fatty liver disease incidence among shrimp and fish by over 30%.
4.
1.
Breakthrough Details Alfa Wassermann developed immobilized enzyme continuous conversion technology for full synthesis of UDCA and CDCA using soybean/rapeseed by-product plant sterols as starting materials, completely decoupling supply from animal bile availability. Process atom economy rose from 66% via traditional extraction to 92.3%, eliminating risks of animal-derived viral contamination. Its Italian production base expanded capacity to 210 tons/year pharmaceutical-grade bile acid in 2025. BASF completed chassis strain transformation for synthetic biology, boosting microbial fermentation precursor conversion efficiency by 41% and shortening fermentation cycles by 35%.
2.
3.
Downstream Benefits Multinational pharmaceutical buyers’ raw material supply is insulated from cyclical global livestock slaughter fluctuations, narrowing annual purchasing quotation volatility from 21% to 7%. Vegetarian-label functional health supplements may legally incorporate bile acid, expanding end-product category portfolios.
4.
1.
Breakthrough Details Japan’s Takeda launched mass production of intestinal targeted sustained-release tauroursodeoxycholic acid derivatives, which remain intact in gastric acid and release active ingredients at fixed intestinal sites, lifting human bioabsorption rates by 27%. Daewoong developed low-irritation pharmaceutical bile acid derivatives with enhanced excipient compatibility, suiting production of soft capsules and injections across multiple dosage forms.
2.
3.
Downstream Benefits Pharmaceutical manufacturers reduce active raw material input volumes by 16% for equivalent-specification formulations, lowering production costs for terminal hepatobiliary medications and improving market competitiveness via lower end-consumer pricing for equivalent drugs.
4.
1.
Breakthrough Details New Zealand NPL commissioned fully automated closed-loop purification production lines with AI real-time chromatographic parameter regulation. Purity fluctuation standard deviation across production batches narrowed from ±0.22% to ±0.06%. Comprehensive production energy consumption fell by 29% versus legacy processes, with full production lines updated with EP/USP/FCC 2025 pharmacopoeia certification documentation.
2.
3.
Downstream Benefits Formulation scrap rates from inconsistent batches dropped by 65% for feed and cosmetic OEM manufacturers, while delivery lead times for small-batch custom orders shortened by 40%.
4.
1.
Procurement Cost Benefits Process iterations by domestic and foreign leading manufacturers drove a 9%–14% average price decline for feed-grade bile acid over the past year, with high-end pharmaceutical-grade prices falling by 8%. Large-scale centralized procurement clients achieve significant annual raw material total cost optimization.
2.
3.
Customs Compliance Benefits All product categories align with the latest EU REACH, US FDA, and Canada AAFCO standards, drastically lowering non-compliance rates during import customs inspection.
4.
5.
End-Application Benefits
6.
· Feed segment: Enables low-protein, antibiotic-free feed formulations and improves livestock and aquatic survival rates.
· Pharmaceutical segment: Accelerates domestic supply of raw materials for NASH fatty liver new drugs and enhances absorption efficiency of special medical foods.
· Cosmetic segment: High-purity bile acid used in repairing skincare formulations reduces raw material compliance costs for end manufacturers.
If you require more comprehensive and valuable Bile Acid market intelligence, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
